Breaking Clinical News Today

The 3-year results show that low-surgical-risk patients undergoing aortic valve replacement continue to show lower rates of all-cause mortality and disabling stroke with TAVR compared with surgery.

Immediate complete revascularization during the index procedure might become the new treatment paradigm in patients with ACS and multivessel disease, results of the BIOVASC trial suggest.

The small interfering RNA product showed reductions of more than 95% in levels of Lp(a) at doses of 75 mg or more when given every 12 weeks in a new phase 2 study.

Late breaker presentation at IDWeek 2022First double-blind registrational phase 3 study in Staphylococcus aureus bacteremiaCeftobiprole non-inferior to...

There’s a lot that will look familiar, but much that’s been revamped, say leaders of the largest US interventional meeting.